ORKA-004
/ Oruka Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 11, 2026
The company is simultaneously expanding the broader pipeline.
(Pulse 2.0)
- "ORKA-004, a half-life extended monoclonal antibody targeting TL1A, is expected to enter clinical development during the fourth quarter of 2026. Oruka plans Phase 2 studies combining ORKA-004 with ORKA-001 and ORKA-002 beginning in 2027."
New P2 trial • Immunology
1 to 1
Of
1
Go to page
1